Sign Up Today and Learn More About Gallant Therapeutics Stock
Invest in or calculate the value of your shares in Gallant Therapeutics or other pre-IPO companies through EquityZen's platform.
Gallant Therapeutics Stock
Gallant Therapeutics is an animal health biotechnology company.
About Gallant Therapeutics Stock
Founded
2018
Headquarters
San Diego, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Gallant Therapeutics Press Mentions
Stay in the know about the latest news on Gallant Therapeutics
Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility
prnewswire • May 06, 2026
Galle Gallants Announce New Ownership Under Gallant Sports and Media LLC Within urban-gro / Flash Sports & Media / IPG–Operated LPL Season 6 Ecosystem; Pubudu Dassanayake Appointed Head Coach
globenewswire • May 04, 2026
Small-cap stocks rebound in April with best month in a decade
economictimes • May 01, 2026
What war? Smallcap stocks defy Middle East tensions with up to 56% gains in 2 months as Nifty slides
economictimes • Apr 30, 2026
Gallant Ispat zooms 64% in 7 days; what's driving stock price?
business-standard • Apr 16, 2026
Gallant Therapeutics Management
Leadership team at Gallant Therapeutics
Senior Vice President Clinical Development & Regulatory
Valentine Williams
Board Member
Richard Jennings
Join now and verify your accreditation status to gain access to:
- Gallant Therapeutics Current Valuation
- Gallant Therapeutics Stock Price
- Gallant Therapeutics Management
- Available deals in Gallant Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Gallant Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Gallant Therapeutics Revenue and Financials
- Gallant Therapeutics Highlights
- Gallant Therapeutics Business Model
- Gallant Therapeutics Risk Factors
- Gallant Therapeutics Research Report from SACRA Research
Trading Gallant Therapeutics Stock
How to invest in Gallant Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Gallant Therapeutics through EquityZen funds. These investments are made available by existing Gallant Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Gallant Therapeutics stock?
Shareholders can sell their Gallant Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 460K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 54K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."